Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis
Clinical Kidney Journal · 04.12.2023 · 16 (Supplement_2) · ii1-ii8
DOI: 10.1093/ckj/sfad199 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 04.12.2023. Verfasst von Mingfeng Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka America Pharmaceutical, Inc..
Abstract (Originalsprache)
Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis, is one of the major causes of end-stage renal disease. Significant variances in epidemiology, clinical manifestation, timing of diagnosis, management and renal prognosis of IgAN have been reported worldwide. The incidence of IgAN is the most frequent in Asia, followed by Europe, and lower in Africa. Moreover, Asian patients show more frequent acute lesions in renal histology and present poorer renal outcomes compared with Caucasians. The comorbidities also show the difference between Asians and Caucasians. Although the frequency of gross hematuria with upper respiratory tract infection is not different, comorbidities with gastrointestinal diseases are reported to be higher in Europe. Recently, genetic studies for variant ethnic patients revealed widely ranging genetic risks in each ethnicity. A genetic risk score is most elevated in Asians, intermediate in Europeans and lowest in Africans, consistent with the disease prevalence of IgAN globally. Ethnic variance might be highly affected by the difference in genetic background. However, it is also essential to mention that the different timing of diagnosis due to variant urinary screening systems and the indication for renal biopsy in different countries may also contribute to these variances. The management of IgAN also varies internationally. Currently, several novel therapies based on the pathogenesis of IgAN are being assessed and are expected to become available soon. Further understanding the ethnic variance of IgAN might help establish individualized care for this disease. Here, we review the issues of ethnic heterogeneities of IgAN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Department of Nephrology, Juntendo University Urayasu Hospital, Chiba, Japan.
- Department of Public Health, Kitasato University School of Medicine, Kanagawa, Japan.
Förderung
- Otsuka America Pharmaceutical, Inc.
Zitieren
APA
Lee, M., Suzuki, H., Nihei, Y., Matsuzaki, K., & Suzuki, Y. (2023). Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis. Clinical Kidney Journal, 16(Supplement_2), ii1-ii8. https://doi.org/10.1093/ckj/sfad199
Vancouver
Lee M, Suzuki H, Nihei Y, Matsuzaki K, Suzuki Y. Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis. Clinical Kidney Journal. 2023;16(Supplement_2):ii1-ii8. doi:10.1093/ckj/sfad199
BibTeX
@article{Lee2023,
author = {Lee, Mingfeng and Suzuki, Hitoshi and Nihei, Yoshihito and Matsuzaki, Keiichi and Suzuki, Yusuke},
title = {Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {Supplement_2},
pages = {ii1--ii8},
doi = {10.1093/ckj/sfad199}
}
EUVIMED